Technology NewsTechnology NewsTechnology News
  • Computing
  • AI
  • Robotics
  • Cybersecurity
  • Electric Vehicle
  • Wearables
  • Gaming
  • Space
Reading: HistoSonics Gains U.K. Access for Edison Tumor Therapy System
Share
Font ResizerAa
Technology NewsTechnology News
Font ResizerAa
Search
  • Computing
  • AI
  • Robotics
  • Cybersecurity
  • Electric Vehicle
  • Wearables
  • Gaming
  • Space
Follow US
  • Cookie Policy (EU)
  • Contact
  • About
© 2025 NEWSLINKER - Powered by LK SOFTWARE
Robotics

HistoSonics Gains U.K. Access for Edison Tumor Therapy System

Highlights

  • Edison gains early U.K. market access via the IDAP program.

  • Insurance reimbursement begins in Michigan for Edison-based liver tumor treatment.

  • More than 50 U.S. medical centers have adopted the Edison system so far.

Samantha Reed
Last updated: 4 June, 2025 - 7:29 pm 7:29 pm
Samantha Reed 2 days ago
Share
SHARE

Noninvasive tumor treatment options for liver cancer are expanding in the United Kingdom following recent regulatory steps by HistoSonics. The company’s Edison histotripsy system, which employs focused ultrasound to mechanically destroy liver tumors without surgery, has been approved for limited early market access through a special U.K. program. This progression not only marks an advancement for HistoSonics but also introduces patients and clinicians in the region to additional therapeutic possibilities besides conventional interventions. Patients dealing with liver tumors may now have an alternative where surgical risk is high or traditional options are limited.

Contents
What Distinguishes the Edison Histotripsy System?What Access and Coverage Does the Device Receive?How Widely Has Edison Been Adopted by Medical Centers?

Regulatory bodies in the U.K. granted Edison’s entry via the Innovative Devices Access Pathway (IDAP), under the Unmet Clinical Need Authorisation. This system’s entry was one of only eight slots available in 2024, making its selection notable for the region’s medical technology landscape. When the Edison device previously gained de novo clearance from the U.S. FDA in October 2023, discussion in industry circles centered on its nonthermal, noninvasive approach. Until this U.K. approval, its utilization was mostly confined to clinical settings within the U.S., where early users provided clinical feedback and helped develop evidence for its safety and efficacy. More recently, media coverage highlighted rumors around HistoSonics’ acquisition talks involving leading medical technology enterprises, underlining the increased interest in focused ultrasound applications, though no confirmed deal was reported as of yet.

What Distinguishes the Edison Histotripsy System?

The Edison system delivers histotripsy treatment by harnessing focused ultrasound energy, which is uniquely mechanical rather than thermal in effect. Guided by a robotic arm, the technology destroys and liquefies cancerous tissue in the liver without requiring incisions or exposing patients to the toxicity typical of chemotherapy or radiation. Clinical use is limited to physicians who have completed specific training from HistoSonics, ensuring standardized procedures across different care settings.

What Access and Coverage Does the Device Receive?

“We are honored to work alongside the NHS and U.K. regulatory and access partners to bring histotripsy to patients across the U.K., many of whom have limited options. This progress builds on our strong clinical track record in the U.S. and our growing base of clinical evidence globally,” said HistoSonics CEO Mike Blue.

Recent months have seen increased support for the Edison system beyond regulatory clearance. Notably, Blue Cross Blue Shield of Michigan and Blue Care Network established medical coverage of nonthermal histotripsy using the Edison system, thus allowing reimbursement for the mechanical destruction of liver tumors as of February 2025. This represents a formal recognition of the procedure’s potential value for eligible patients in the United States, ahead of broader coverage set to begin in July.

How Widely Has Edison Been Adopted by Medical Centers?

The Edison Histotripsy System’s deployment has expanded to more than 50 major medical institutions in the U.S., where it has been used to treat over 1,500 patients according to company figures. Surgeons, radiologists, and oncologists have integrated Edison into various care strategies for both primary and metastatic liver tumors, contributing to a growing pool of clinical data and user experience.

Wider adoption and insurance coverage for focused ultrasound-based therapies such as Edison signal a gradual shift towards noninvasive solutions where possible. Before using such a system, both patients and clinicians must consider the specifics of tumor location, existing health conditions, and the expertise required for operation. As clinical evidence accumulates and coverage expands, medical professionals are likely to compare focused ultrasound to established surgical, ablative, or pharmacological options. For patients seeking alternatives to conventional liver tumor treatments, understanding new device-based approaches—including their candidacy, process, and known outcomes—can help them make informed decisions. Staying updated on new approvals, insurance arrangements, and potential acquisition moves among technology providers may offer patients insight into the evolving landscape of cancer care devices.

You can follow us on Youtube, Telegram, Facebook, Linkedin, Twitter ( X ), Mastodon and Bluesky

You Might Also Like

Simbe Rolls Out Inventory Robots at DeCicco & Sons Stores

Whale Dynamic and Noodoe Launch Integrated Autonomous Delivery Ecosystem

Johnson & Johnson Reports High Success Rates With Monarch Surgery Platform

Experts Highlight How Gearboxes Power Warehouse Robotics

Robotics Innovations Drive Industry Forward at Major 2025 Trade Shows

Share This Article
Facebook Twitter Copy Link Print
Samantha Reed
By Samantha Reed
Samantha Reed is a 40-year-old, New York-based technology and popular science editor with a degree in journalism. After beginning her career at various media outlets, her passion and area of expertise led her to a significant position at Newslinker. Specializing in tracking the latest developments in the world of technology and science, Samantha excels at presenting complex subjects in a clear and understandable manner to her readers. Through her work at Newslinker, she enlightens a knowledge-thirsty audience, highlighting the role of technology and science in our lives.
Previous Article Whale Dynamic and Noodoe Launch Integrated Autonomous Delivery Ecosystem
Next Article Lucid Targets Tesla Owners With $4,000 Trade-In Incentive

Stay Connected

6.2kLike
8kFollow
2.3kSubscribe
1.7kFollow

Latest News

Players Tackle Challenging Wordle Puzzle as ‘EDIFY’ Emerges
Gaming
U.S. Authorities Seize $7.7M Linked to North Korean Crypto Laundering
Cybersecurity
Tesla Update Lets Drivers Easily Unlatch Third-Party Chargers
Electric Vehicle
23andMe Faces New Ownership Battle as Higher Bid Triggers Fresh Auction
Technology
Sean Cairncross Outlines Cyber Coordination Plans to Senate Panel
Cybersecurity
NEWSLINKER – your premier source for the latest updates in ai, robotics, electric vehicle, gaming, and technology. We are dedicated to bringing you the most accurate, timely, and engaging content from across these dynamic industries. Join us on our journey of discovery and stay informed in this ever-evolving digital age.

ARTIFICAL INTELLIGENCE

  • Can Artificial Intelligence Achieve Consciousness?
  • What is Artificial Intelligence (AI)?
  • How does Artificial Intelligence Work?
  • Will AI Take Over the World?
  • What Is OpenAI?
  • What is Artifical General Intelligence?

ELECTRIC VEHICLE

  • What is Electric Vehicle in Simple Words?
  • How do Electric Cars Work?
  • What is the Advantage and Disadvantage of Electric Cars?
  • Is Electric Car the Future?

RESEARCH

  • Robotics Market Research & Report
  • Everything you need to know about IoT
  • What Is Wearable Technology?
  • What is FANUC Robotics?
  • What is Anthropic AI?
Technology NewsTechnology News
Follow US
About Us   -  Cookie Policy   -   Contact

© 2025 NEWSLINKER. Powered by LK SOFTWARE
Welcome Back!

Sign in to your account

Register Lost your password?